Do elevated stool zonulin family peptide and fecal secretory IgA suggest increased intestinal permeability signaling and mucosal immune activation?

Assessments of gut barrier integrity and mucosal immunity frequently rely on stool biomarkers, but their clinical precision and diagnostic utility vary significantly.

Clinical and diagnostic evidence

• Fecal Secretory IgA (sIgA): Elevated fecal sIgA is a highly validated indicator of active mucosal immune activation. Local plasma cells upregulate sIgA in response to luminal threats such as enteric infections, dysbiosis, or dietary antigens. However, it is a non-specific marker that cannot independently differentiate between specific etiologies, such as distinguishing irritable bowel syndrome (IBS) from active inflammatory bowel disease (IBD).
• Stool Zonulin Family Peptide (ZFP): While elevated ZFP is a plausible marker of altered barrier signaling, its diagnostic utility is heavily constrained. Commercial ZFP ELISA assays lack specificity, cross-reacting with complement pathway proteins (such as properdin) rather than true pre-haptoglobin-2 (native zonulin). Consequently, stool ZFP values correlate poorly with gold-standard functional tests, such as the lactulose-mannitol dual-sugar absorption test.

Mechanistic pathways and mucosal signaling

• Tight Junction Regulation: Native zonulin physiologically modulates epithelial tight junctions to regulate paracellular permeability. Mucosal inflammation and alterations in the gut microbiota trigger its release, linking elevated levels to barrier compromise.
• Humoral Defense and Permeability: Secretory IgA serves as the primary immunological barrier in mucosal secretions. Persistently elevated fecal sIgA levels correlate with intestinal barrier dysfunction and gut permeability markers, reflecting a coordinated humoral response to active luminal challenges and mucosal stress.

Bottom line

• Elevated fecal sIgA reliably indicates active mucosal immune defenses and barrier stress, whereas elevated stool ZFP is a plausible but weakly validated marker of permeability signaling due to significant assay cross-reactivity. Neither marker should be used as a standalone diagnostic tool without broader clinical correlation.